crta
Hrvatska znanstvena Sekcija img
bibliografija
3 gif
 Naslovna
 O projektu
 FAQ
 Kontakt
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Upute
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 821741

Časopis

Autori: Barbour SJ; Espino-Hernandez G; Reich HN; Coppo R; Roberts IS; Feehally J; Herzenberg AM; Cattran DC; Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia.
Naslov: The MEST score provides earlier risk prediction in lgA nephropathy
( The MEST score provides earlier risk prediction in lgA nephropathy )
Izvornik: Kidney international (0085-2538) 89 (2016), 1; 167-175
Vrsta rada: članak
Ključne riječi: IgA nephropathy ; glomerular disease ; renal pathology
( IgA nephropathy ; glomerular disease ; renal pathology )
Sažetak:
The Oxford Classification of IgA nephropathy (IgAN) includes the following four histologic components: mesangial (M) and endocapillary (E) hypercellularity, segmental sclerosis (S) and interstitial fibrosis/tubular atrophy (T). These combine to form the MEST score and are independently associated with renal outcome. Current prediction and risk stratification in IgAN requires clinical data over 2 years of follow-up. Using modern prediction tools, we examined whether combining MEST with cross- sectional clinical data at biopsy provides earlier risk prediction in IgAN than current best methods that use 2 years of follow-up data. We used a cohort of 901 adults with IgAN from the Oxford derivation and North American validation studies and the VALIGA study followed for a median of 5.6 years to analyze the primary outcome (50% decrease in eGFR or ESRD) using Cox regression models. Covariates of clinical data at biopsy (eGFR, proteinuria, MAP) with or without MEST, and then 2-year clinical data alone (2-year average of proteinuria/MAP, eGFR at biopsy) were considered. There was significant improvement in prediction by adding MEST to clinical data at biopsy. The combination predicted the outcome as well as the 2-year clinical data alone, with comparable calibration curves. This effect did not change in subgroups treated or not with RAS blockade or immunosuppression. Thus, combining the MEST score with cross-sectional clinical data at biopsy provides earlier risk prediction in IgAN than our current best methods.
Projekt / tema: 198-0000000-3355
Izvorni jezik: eng
Rad je indeksiran u
bazama podataka:
Current Contents Connect (CCC)
MEDLINE
Scopus
SCI-EXP, SSCI i/ili A&HCI
Science Citation Index Expanded (SCI-EXP) (sastavni dio Web of Science Core Collectiona)
Kategorija: Znanstveni
Znanstvena područja:
Kliničke medicinske znanosti
URL Internet adrese: http://www.sciencedirect.com/science/article/pii/S0085253815000459
Broj citata:
Altmetric:
DOI: 10.1038/ki.2015.322
URL cjelovitog teksta:
Google Scholar: The MEST score provides earlier risk prediction in lgA nephropathy
Upisao u CROSBI: Danica Ljubanović (danica.ljubanovic@zg.t-com.hr), 15. Lip. 2016. u 20:43 sati
Napomene:
Group Author(s): VALIGA Study (hrvatski suradnici: Krešimir Galešić i Danica Galešić-Ljubanović)



  Verzija za printanje   za tiskati


upomoc
foot_4